Psilocybin Plus Psychotherapy Offers Lasting Benefit in Cancer, Depression
MONDAY, June 16, 2025 -- For cancer patients with a major depressive disorder, a single dose of psilocybin combined with psychological support can provide sustained relief for depression and anxiety, according to a study published online June 16 in Cancer.
Manish Agrawal, M.D., from Sunstone Therapies in Rockville, Maryland, and colleagues examined efficacy outcomes at two years for patients enrolled in a phase 2 trial that demonstrated safety, feasibility, and efficacy of a single dose of psilocybin combined with psychological support in a community cancer setting involving 30 patients with cancer and a major depressive disorder.
The researchers found that 15 of 28 patients (53.6 percent) had a significant reduction in depression as measured by the Montgomery Asberg Depression Rating Scale (average, −15.0 points from baseline) and 14 (50 percent) had a sustained reduction in depression. Overall, 13 patients (46.4 percent) experienced a significant reduction in anxiety as measured by the Hamilton Anxiety Rating Scale (average, −13.9 points from baseline), and 12 (42.9 percent) experienced a sustained reduction in anxiety.
"One dose of psilocybin with psychological support to treat depression has a long-term positive impact on relieving depression for as much as two years for a substantial portion of patients with cancer, and we're exploring whether repeating the treatment resolves depression for more than half of the patients," Agrawal said in a statement.
Several authors disclosed ties to industry, including Sunstone Therapies.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Drop in Hospital Salaries, Staffing Reported After Private Equity Acquisitions
FRIDAY, Sept. 26, 2025 -- U.S. hospitals that undergo private equity acquisition may reduce salaries and staffing after acquisition, especially in emergency departments (EDs) and...
Poor Mental Health Outcomes More Likely With Hyperemesis Gravidarum
FRIDAY, Sept. 26, 2025 -- Hyperemesis gravidarum is associated with an increased risk for poorer mental health outcomes compared with pregnancy without hyperemesis gravidarum...
Young Adult Cancer Survivors Face Higher Social Risks
FRIDAY, Sept. 26, 2025 -- Young adult cancer survivors face elevated social risks, according to a study presented at the 18th AACR Conference on the Science of Cancer Health...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.